Neurocrine Biosciences | NBIX - Net Income

Stock Price
158.42
Daily Change
-0.63 -0.40%
Monthly
23.37%
Yearly
30.90%
Q2 Forecast
155.24

Neurocrine Biosciences reported $197.9M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
ALKERMES USD -66.48M 115.82M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Exelixis USD 210.47M 34.06M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Prothena USD -21.59M 14.95M Dec/2025
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Repligen USD 8.33M 4.95M Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Teva Pharmaceutical Industries USD 369M 111M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026
Xoma USD -17.24M 33.23M Sep/2024